ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2282

Ferritin Levels Are Associated with Urate and Gout – a Role for Iron Metabolism in Gout ?

Tahzeeb Fatima1, Tony R. Merriman2, Lisa K. Stamp3, Nicola Dalbeth4, Cory Iverson5 and Jeffrey N. Miner6, 1University of Otago, Dunedin, New Zealand, 2Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 3University of Otago, Christchurch, New Zealand, 4University of Auckland, Auckland, New Zealand, 5Ardea Biosciences, Inc., San Diego, CA, 6Discovery Biology, Ardea Biosciences, Inc., San Diego, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Gout and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Transferrin and its cell-surface receptor regulate iron uptake and ferritin sequesters free iron and acts as a store for excess iron. Ferritin has been positively associated with serum urate in the National Health and Nutrition Examination Survey III [1]. There have been observational and interventional studies suggesting a role for iron as a trigger for gout flares, which may be due to pro-inflammatory activities associated with iron [2]. Consistent with this, genetic variation in the transferrin receptor has been associated with gout and with an increased likelihood of self-report of an iron-rich food as a trigger of flares [3]. This observational study aimed to replicate the association of serum ferritin with serum urate (SU) and to test for association of serum ferritin with gout.

Methods: Association with gout was assessed in European (100 cases, 60 controls) and Polynesian (100 cases, 60 controls) male individuals from New Zealand (NZ) and a mixture of Latino, African American and European (33 cases, 60 controls) individuals from the United States (US). People with liver damage/ disease were excluded. For the SU association analysis, 180 participants without gout from NZ and the US and an additional 1,260 participants from the Jackson Heart Study (JHS) were used. Participants taking diuretic medication, or who had kidney disease or gout or first-degree relatives with gout were excluded from the SU analysis. Multiple regression analyses adjusted for age, sex (where relevant) and body mass index were done using R v3.3.0. Self-reported grandparental ancestry (for Polynesian) and C-reactive protein level (for JHS and US) were also included as covariates in the various analyses. Beta and OR statistics are expressed per 10 ng/mL increase in ferritin.

Results: Serum ferritin was positively associated with gout in NZ Polynesian [OR=1.031, P=4.4E-03] and US [OR=1.214, P=6.9E-05] participants but not NZ Europeans [OR=0.997, P=0.84] (Table). A positive association of ferritin with urate was observed in both NZ Polynesian [ß=0.081 µmol/L, P=1.1E-03] and US [ß=0.29 µmol/L, P=4.3E-06] individuals but not in NZ Europeans [ß=0.052 µmol/L, P=0.33]. A positive association of serum ferritin with SU was found in both males (ß=0.046 µmol/L, P=9.3E-03) and females (ß=0.081 µmol/L, P=1.6E-03) in the JHS.

Conclusion: The association of ferritin with SU and gout was independent of C-reactive protein level, suggesting that the relationship is not due to the elevation of ferritin in inflammation [4] and consistent with a direct role for iron metabolism in the control of SU and gout. This is supported by the previous report of association of the transferrin receptor with gout. 1. Ghio et al. Free Radic Res. 2005;39:337-42. 2. Facchini. Rheumatology. 2003;42:1550-55. 3. Merriman et al. Arthritis Rheumatol.2015;S67(10). 4. Kell et al. Metallomics, 2014. 6:748-73.

Population

Serum Urate [µmol /L]

Gout [case/control]

NU/HU

Beta [95% CI]

P

OR [95% CI]

P

OR [95% CI]

P

JHS (males)

0.046 [0.011 – 0.080]

9.3E-03

–

–

1.012 [1.010 – 1.023]

1.4E-02

JHS (females)

0.081 [0.030 – 0.131]

1.6E-03

–

–

1.040 [1.011 – 1.067]

3.3E-03

JHS (combined)

0.059 [0.031 – 0.087]

3.2E-05

–

–

1.016 [1.010 – 1.026]

1.1E-03

NZ European

0.052 [-0.055 – 0.159]

0.33

0.997 [0.973 – 1.023]

0.84

1.010 [0.984 – 1.024]

0.65

NZ Polynesian

0.081 [0.033 – 0.129]

1.1E-03

1.031 [1.011 – 1.046]

4.4E-03

1.021 [1.011 – 1.031]

8.6E-04

US

0.296 [0.176 – 0.417]

4.3E-06

1.214 [1.120 – 1.358]

6.9E-05

1.056 [1.021 – 1.101]

3.7E-03


Disclosure: T. Fatima, None; T. R. Merriman, None; L. K. Stamp, None; N. Dalbeth, None; C. Iverson, AstraZeneca, 3,AstraZeneca, 1; J. N. Miner, Ardea Biosciences, Inc., a member of the AstraZeneca Group, 3.

To cite this abstract in AMA style:

Fatima T, Merriman TR, Stamp LK, Dalbeth N, Iverson C, Miner JN. Ferritin Levels Are Associated with Urate and Gout – a Role for Iron Metabolism in Gout ? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/ferritin-levels-are-associated-with-urate-and-gout-a-role-for-iron-metabolism-in-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ferritin-levels-are-associated-with-urate-and-gout-a-role-for-iron-metabolism-in-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology